Swiss clinical-stage biotech AC Immune today announced positive interim safety and efficacy results from the Phase II VacSYn ...

As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, ...

Swiss pharma giant Roche (SIX: ROG) has announced positive data from the Phase III lidERA Breast Cancer study of giredestrant ...

The bipolar disorder market across the USA, Europe, and Japan is forecast to rise from $5.6 billion in 2024 to $9.4 billion ...

German biotech Disco Pharmaceuticals has appointed Mark Manfredi as chief executive and closed a 36 million euro ($39 million ...

For decades, the generics industry has been dedicated to supporting the financial sustainability of health systems. By ...

Hong Kong-based Ascletis Pharma has announced that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, ...

The diagnosed prevalent cases of diabetic macular edema (DME) in the diabetes population across the seven major markets (7MM: ...

Diakonos Oncology has received more than $7 million from the Cancer Prevention and Research Institute of Texas to support a ...

Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been ...

Privately-held BlossomHill Therapeutics, a US biopharma focused on the design and development of next-generation medicines ...

PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics (Nasdaq: MCRB) chief executive Eric ...